New drug cocktail shows promise for Hard-to-Treat cancers

NCT ID NCT03502733

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor side effects. The study involves about 64 adults whose cancer has progressed after standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Copanlisib (a targeted drug) combined with nivolumab and/or ipilimumab (immunotherapy drugs)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors or lymphoma that has not responded to standard therapies.
What could go wrong: This is an early phase 1 trial with only 64 participants, so the combination may prove too toxic or not effective enough to move forward. Side effects from both the targeted drug and immunotherapies can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lymphoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA METASTATIC MALIGNANT SOLID NEOPLASM RECURRENT MALIGNANT SOLID NEOPLASM UNRESECTABLE MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

National Cancer Institute Developmental Therapeutics Clinic

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.